← Leaderboards
Johannes Nowatzky
New York University School Of Medicine
$4,843,429
Attributed
$4,843,429
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $881.4K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,843,429 · 3
By mechanism
R01$3,936,639 · 2
K08$906,790 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Shukti Chakravarti$13,351,356
- Elisabeth J Cohen$6,899,640
- Judith S Hochman$132,321,589
- Rockland L Wiseman$20,297,675
- Ian J. Mohr$18,844,159
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingAutoimmunityT Cell ResponseTargeted TreatmentCellsInflammationUveitisAffectEffector T CellPublishingGenetic PolymorphismCd8-Positive T-LymphocytesGenetic EpistasisImmune ResponsePeptidesEndoplasmic ReticulumBlindnessHaplotypesGenome EditingHigh RiskCd8b1 GeneCrispr/Cas TechnologyImmune System DiseasesLiterature
Grant awards (16)
Modulation of immunodominance in HLA class I associated uveitides$292,988
R01 · FY2025 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$227,700
R01 · FY2025 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$196,050
R01 · FY2025 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$164,662
R01 · FY2025 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$457,650
R01 · FY2024 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$423,750
R01 · FY2024 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$457,650
R01 · FY2023 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$423,751
R01 · FY2023 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$457,650
R01 · FY2022 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$411,038
R01 · FY2022 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in BehcetâÃâ¬Ãâ¢s eye disease$423,750
R01 · FY2021 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2019 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2018 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2017 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2016 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2015 · EY · contact PI